Keeping weight off after stopping Ozempic or Wegovy

In the STEP 1 extension, every participant came off treatment at week 68 and was weighed again at week 120, a year after the last dose. The 327 people in the extension analysis set regained 11.6 percentage points of lost weight (SD 7.7) in the semaglutide arm, against 1.9 percentage points (SD 4.8) in the arm that had been on placebo (Wilding et al., Diabetes, Obesity and Metabolism, August 2022). That is roughly two thirds of what the semaglutide group had lost. In absolute terms, mean body weight in that group went from 87.5 kg at week 68 to 99.0 kg at week 120.

A third of the loss stayed. Net change from week 0 to week 120 was 5.6% (SD 8.9%) for the semaglutide group and 0.1% (SD 5.8%) for placebo (Wilding 2022). Blood pressure and most of the lipid improvements reverted toward baseline over that year, while improvements in LDL cholesterol, C-reactive protein, and HDL cholesterol held against baseline.

STEP 4 ran the comparison the other way around. Everyone took semaglutide through a 20-week run-in and mean body weight declined by 10.6%, then 803 people who had reached the 2.4 mg dose were randomized either to continue or to switch to placebo (Rubino et al., JAMA, March 23, 2021). From week 20 to week 68, the 535 who continued lost a further 7.9% and the 268 who switched to placebo gained 6.9%, a difference of 14.8 percentage points (95% CI 13.5 to 16.0).

The Wegovy label carries this trial as Study 5 and prints a caveat with it. Because patients who discontinued during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized treatment period, the results may not reflect the experience of patients in the general population who are first starting Wegovy (Wegovy prescribing information, revised 08/2025).

A 2026 systematic review included 48 studies and modeled the regain curve from six randomized trials covering 3,236 participants. At one year after cessation, 60% of the weight lost during treatment had been regained, and the modeled curve plateaus at 75.3% of the weight lost (95% CI 68.9 to 81.6), which leaves about a quarter of the loss in place (eClinicalMedicine, March 2026). Regain follows a decelerating pattern with a rate constant of 0.0302 per week, a half-life of 23.0 weeks, and the trajectories looked broadly similar across trials of liraglutide, semaglutide, and tirzepatide.

The authors put a limit on their own curve. Trial data runs only to 52 weeks after cessation, so anything past that window is extrapolation (eClinicalMedicine, March 2026).

A retrospective cohort of 7,938 adults at one health system in Ohio and Florida followed people for a year after they stopped a GLP-1. Those treated for obesity had lost an average of 8.4% of body weight before stopping and had regained 0.5% one year later, and those treated for type 2 diabetes had lost 4.4% and went on to lose a further 1.3% (Cleveland Clinic, published in Diabetes, Obesity and Metabolism, announced March 12, 2026).

Part of that flat line comes from people going back on something. Within 12 months, 20% had restarted their original medication and 27% had switched to a different one, including older obesity medications (Cleveland Clinic, March 12, 2026). This is one retrospective cohort in two states, so it describes that group and predicts nothing about you, and it sits next to the trial numbers above rather than replacing them.

Wegovy is indicated in combination with a reduced calorie diet and increased physical activity, and one of its stated indications is to reduce excess body weight and maintain weight reduction long term (Wegovy prescribing information, revised 08/2025). The diet and the activity are written into the indication itself, so they were meant to be running alongside the drug the whole time rather than starting after it.

Ozempic is a different label with a different job. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and it carries no weight-management indication (Ozempic prescribing information, revised May 2026). MedlinePlus adds the line that covers both drugs, that semaglutide injection helps to control diabetes and weight loss but does not cure it, and it tells you to follow all exercise and dietary recommendations made by your doctor or dietitian (MedlinePlus, updated 05/15/2026).

MedlinePlus puts protein for healthy adults at 10% to 35% of your total calorie needs, and it gives the arithmetic, that one gram supplies 4 calories, so 100 grams of protein in a 2,000-calorie day is 20% of the total (MedlinePlus, review date 04/01/2025). That is a range rather than a target, and yours gets set inside it by you and whoever knows your history.

The CDC puts adult activity at 150 minutes of moderate-intensity physical activity a week, or 75 minutes of vigorous-intensity, or an equivalent combination of the two, plus at least 2 days of muscle-strengthening activity that works all major muscle groups, meaning legs, hips, back, abdomen, chest, shoulders, and arms (CDC, last updated December 20, 2023). Nothing on this page tells you to start any of that, because clearing you for exercise belongs to your prescriber.

I never tell you to stop, taper, pause, or restart, and I never touch a dose. Those decisions belong to your prescriber, and when you ask me about them I send you back to that office. I do not diagnose, I do not clear you for exercise, and I never set a calorie target below what your dietitian or your prescriber gave you.

The daily part is what I am for. You text me the food and I log it with the calories and protein, because appetite returns after the last dose and a running log catches that in the first week instead of the third month. We pick movement you will actually keep, and walking counts, and your steps come from your phone. Once a week I send a recap with the weight trend so you are reading weeks instead of mornings. When a target keeps getting missed, I say the target is wrong for your life and we change it.

No clinician reviewed this page. It restates the STEP 1 extension, STEP 4, the eClinicalMedicine meta-regression, the Cleveland Clinic cohort, the Wegovy and Ozempic prescribing information, MedlinePlus, and the CDC, all linked below, and those are the documents to trust over anything here.